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OBJECTIVE — To determine whether C-terminal provasopressin (copeptin) explains the
prognostic importance of insulin growth factor binding protein-1 (IGFBP-1) in patients with
myocardial infarction and type 2 diabetes.
RESEARCHDESIGNANDMETHODS — CopeptinandIGFBP-1wereanalyzedin393
patients participating in the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial
Infarction (DIGAMI) 2 trial.
RESULTS — Copeptin was associated with IGFBP-1 (Spearman rank correlation test, r 
0.53;P0.001).Duringfollow-uptherewere138cardiovascularevents(cardiovasculardeath,
myocardial infarction, and stroke). In univariate Cox proportional hazard regression analyses
both biomarkers were predictors of events: the hazard ratio for log copeptin was 1.59 (95% CI
1.41–1.81;P0.001)andforlogIGFBP-1was1.49(1.26–1.77;P0.001).Intheﬁnalmodel,
adjusting for age and renal function, copeptin was the only independent predictor (1.35 [1.16–
1.57]; P  0.001).
CONCLUSIONS — Copeptin is an independent predictor of cardiovascular events and ap-
pears to at least partly explain the prognostic impact of IGFBP-1 in patients with type 2 diabetes
and myocardial infarction. Copeptin may be a pathogenic factor to address to improve outcome
in these patients.
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C
opeptin,theC-terminaldegradation
partofthevasopressinprehormone,
is a stable peptide suitable as a
markerfortheargininevasopressin(AVP)
system (1,2), which is activated by stress
and plays an essential role in osmoregu-
lationandthecontrolofvasculartone(3).
High levels of copeptin are linked to im-
paired cardiovascular prognosis (4). An-
other factor related to cardiovascular
prognosisisinsulingrowthfactorbinding
protein-1 (IGFBP-1), which modulates
IGF-1 bioavailability (5,6). There may be
a link between the AVP and IGF-1 sys-
tems since infusions of desmopressin, a
vasopressin agonist, in patients with dia-
betes insipidus had a direct impact on
IGFBP-1 levels (7).
This report, a substudy of the Diabe-
tes Mellitus Insulin-Glucose Infusion in
Acute Myocardial Infarction (DIGAMI) 2
trial, analyzes whether copeptin explains
the prognostic importance of IGFBP-1 in
patients with diabetes and myocardial
infarction.
RESEARCH DESIGN AND
METHODS— Copeptin and IGFBP-1
were measured at hospital admission in
393 patients of the DIGAMI 2 cohort (8,
online appendix Figure 1 available at
http://care.diabetesjournals.org/cgi/content/
full/dc10-0088/DC1). Copeptin was mea-
sured with a sandwich immunoassay
(LUMI test C-terminal pro-AVP; BRAMHS,
Henningsdorf/Berlin,Germany;lowerde-
tection limit 0.4 pmol/l, functional assay
sensitivity [20% interassay coefﬁcient
ofvariation]1pmol/l)(1,2).TheIGFBP-1
concentrations in serum were determined
by radioimmunoassay (sensitivity 3 g/l
and cardiovascular intra- and interassays 3
and 10%, respectively) according to Po ´voa
et al. (9).
Statistical methods
Differences between groups were as-
sessed with Kruskal-Wallis, Jonckheere-
Terpstra, or log-rank tests for trend. The
association between continuous variables
was studied with the Spearman rank cor-
relation. Cox proportional hazard regres-
sion assessed the relation between
copeptin, IGFBP-1, and cardiovascular
events (a composite of cardiovascular
death and nonfatal myocardial infarction
or stroke). Known predictors of outcome
in the DIGAMI 2 trial (age, creatinine
clearance, glucose at admission, and
previousheartfailure)wereadjustedfor
in univariable analyses. Age and creati-
nine clearance remained signiﬁcant and
wereincludedintheﬁnalmodel.Atwo-
tailed P  0.05 was considered signiﬁ-
cant (SAS 9.2).
RESULTS— For patient characteris-
tics see online appendix Table 1. Copep-
tin varied between 0.97 and 1936.0
pmol/l (median 21.8; mean 62.4) and
IGFBP-1 between 3.0 and 677.0 g/l
(median 23.0, mean 42.0).
During follow-up (median 2.5 years),
cardiovascular events increased by in-
creasing copeptin tertiles (log-rank test
P  0.0001; online appendix Fig. 3).
Moreover, cardiovascular deaths within
90 days were related to higher copeptin
levels at baseline (Jonckheere-Terpstra
test P  0.0001; online appendix).
Therewasasigniﬁcantcorrelationbe-
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correlation coefﬁcient 0.53; P  0.001;
online appendix Table 2). Both biomark-
ers correlated with age, BMI, creatinine
clearance,andbloodglucosebutnotwith
A1C. Sex did not inﬂuence copeptin lev-
els,buthigherlevelswereseeninpatients
abovethemedianage,withrenalfunction
below or glucose levels above the median
and in those with known heart failure.
IGFBP-1 was higher in women and those
above the median age or with renal func-
tionbeloworglucoselevelsabovetheme-
dian (online appendix Table 2).
Copeptin and IGFBP-1 were signiﬁ-
cant predictors of cardiovascular events
in unadjusted analysis (Table 1). In the
ﬁnal model, adjusting for age and creati-
nine clearance, copeptin remained an in-
dependent predictor.
CONCLUSIONS — The present ob-
servationofacorrelationbetweenthelev-
els of copeptin and IGFBP-1, combined
with the stimulatory effect of desmopres-
sinonIGFBP-1(7),suggestsapathogenic
relationship between vasopressin and
IGFBP-1.
Activation of the AVP system, mainly
regulated by serum osmolality (10), may
be detrimental in patients with myocar-
dial infarction by increasing left ventricu-
lar afterload due to vasoconstriction and
preload due to renal water reabsorbtion
(10). This study adds IGFBP-1 as a new
effectorofvasopressin-mediatedstressre-
sponse in myocardial infarction. The ex-
act reasons are unclear, but there are
plausible explanations.
IGFBP-1 modulates the bioavailable
levels of IGF-1 and has both direct and
IGF-1–mediated effects (11). IGFBP-1 is
mainly produced by the liver (5) and
largely regulated by inhibitory effects of
insulin (12). The ratio between IGFBP-1
and insulin is increased in patients with
myocardial infarction (6) and critical ill-
ness (13), perhaps as a consequence of
hepatic insulin resistance induced by
hypoxia and proinﬂammatory cytokines
(11–13).
The newly described relationship be-
tween copeptin and insulin resistance
(14) adds to this relation with a poten-
tially negative impact on cardiovascular
outcome. Another possibility is that
IGFBP-1 activation may be a result of va-
sopressin receptor activation. This might
have therapeutic implications because
clinical trials with antagonists of these re-
ceptors (vaptans) have produced mixed
results, however, so far without cardio-
vascular beneﬁts. It may be that the
present vaptans act on the wrong set of
receptors in the present clinical scenario.
Copeptin was higher in patients with pre-
viously known heart failure. Indeed heart
failure, a predictor of events in the
DIGAMI 2 trial, disappeared after adjust-
ing for copeptin, indicating a pathogenic
relationship.
The copeptin levels in this present
population are higher than those de-
scribed in healthy individuals (2) but not
higher than in other patients with myo-
cardial infarction, although copeptin
seems elevated in patients with diabetes
(4). This may reﬂect the high proportion
of glucometabolic perturbations in pa-
tients with myocardial infarction (15).
This study has limitations. Although
it was a prospectively planned biochemi-
calpartoftheDIGAMI2trial,thisstudyis
of observational character and thereby
limited to the available subpopulation.
The lack of a measure of hemodynamic
confounders such as serum osmolality
may be seen as draw back. However,
copeptin and IGFBP-1 were intentionally
sampled soon after hospital admission,
i.e., before the initiation of study-related
or other treatments that could have inﬂu-
enced the biomarkers.
In conclusion, copeptin is an inde-
pendent predictor of cardiovascular
events and appears, at least partly, to ex-
plaintheprognosticimpactofIGFBP-1in
patientswithtype2diabetesandmyocar-
dialinfarction.Thepresentresultsarehy-
pothesis generating, encouraging further
studiesonthepathophysiologicalrelation
between copeptin and IGFBP-1 and
whether copeptin per se is a factor to be
addressed in order to improve the out-
come in these patients.
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